Humana Raises 2026 Earnings Outlook After Third-Quarter Revenue Jumps 26%
Humana (HUM) reported Q3 2026 earnings with a narrower-than-expected loss of $0.70 per share and 26% revenue growth to $41.16B. It raised its full-year EPS guidance to at least $9.50, exceeding estimates. Shares fell 0.8% despite the positive outlook.
How this was made
The 30-second read
Why it matters
The guidance raise is a primary corporate event that could influence analyst forecasts and sector sentiment, though the immediate market reaction was muted.
Market read
First‑report earnings and guidance lift for a large‑cap health insurer; traders may adjust positions based on the new outlook.
What to watch
Medicaid membership growth and CenterWell primary‑care expansion could drive longer‑term earnings upside not fully reflected in the current price.
Background
Humana reported Q3 2026 results with revenue of $41.16 B (+26% YoY) and a loss of $0.70 per share, better than expectations, and announced higher FY guidance.
Ticker impact
Humana raised its FY2026 adjusted earnings guidance to at least $9.50 per share and GAAP earnings to at least $15.09, after reporting a 26% revenue jump and a narrower loss than expected.
modest downside as the market digests the guidance despite the raise
The new guidance is material and fresh, but the immediate price reaction was negative, suggesting traders may be cautious.
Market effects
Higher earnings outlook may lift the broader health‑insurer sector, but modest price reaction tempers the effect.
U.S. health‑care stocks could see slight upward pressure in after‑hours trading.
Limited; primarily U.S. market impact.
Counterpoint
Despite the guidance raise, the share price dip suggests the market may have already priced in the improvement, offering a potential buying opportunity if the trend holds.
Key entities
- ExecutiveJim Rechtin
CEO of Humana who highlighted operational improvements.
